Please turn JavaScript on
header-image

Multidisciplinary Association for Psychedelic Studies – MAPS

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.07 / day

Message History

Washington, DC; February 4, 2026 — With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a r...


Read full story

February 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announces a formal research partnership with Columbia University to study how practitioners are facilitating MDMA-assisted couples therapy in real-world settings. This first-of-its-kind study will conduct surveys and interviews with practitioners currently fac...


Read full story

January 14, 2026 — In October 2025, Joe Green and Miriam Volat resigned their positions as members of the MAPS Board of Directors.

Mr. Green joined the MAPS board in December 2020 and — among other things — raised key funds and laid critical groundwork for MAPS Public Benefit Corporation’s evolution, first into Lykos Therapeutics an...


Read full story
Training supports multi-site clinical trial of MDMA-assisted Massed Prolonged Exposure Therapy for PTSD in active-duty service members. First-of-its-kind therapist preparation supports the Department of Defense-funded study, ensuring clinicians research MDMA-assisted therapy with foundational skills and support. Adapted training model demonstrates ho...

Read full story

The executive order to reschedule cannabis marks a symbolic victory and a recalibration of decades of federal misclassification. Reclassifying cannabis as a Schedule III substance is a long-overdue acknowledgment of its medical utility and a sharp rhetorical shift from Washington.
But symbolism is not structural reform.

Rescheduling alone w...


Read full story